Introduction
Since the 1970s, health professionals in Thailand have played an important public role in health sector reform, sometimes risking their professional positions but often emerging with enhanced public standing (Bamber 1997) . In 1985, civic groups joined their efforts by lobbying (initially with little success) against increasingly restrictive patent legislation for pharmaceuticals, which in their view limited access to affordable medicines.
In 1998, civil society involvement in health advocacy was reinforced with the establishment of the Thai Network of People with HIV ⁄ AIDS (TNP+). Motivated by a combination of despair in front of death, a strong desire to help friends who fell ill, and anger at a system that made life-saving medicines unaffordable for the majority, people with HIV ⁄ AIDS (PHA) have developed a central role in advocacy for improved access to AIDS drugs and have also promoted a patient-centred approach to HIV ⁄ AIDS care within the public health sector. Their role is recognized by the Ministry of Public Health as central to the successful expansion of antiretroviral treatment through activities that encourage community education, reduce discrimination, provide peer support, and promote the right of government to make and use affordable generic drugs (Kunaratanapruk 2004) .
Treatment activism has brought civic groups (Table 1) together to fight for a single cause, creating a platform for joint action on practical issues to improve care within the public health system. We describe the main activities of three groups over the last decade: AIDS ACCESS Foundation, the TNP+ and Médecins Sans Frontières (MSF). Their efforts have implicated PHA in treatment activism and as co-providers of care within the public health system. This article, written by representatives of these three groups, aims to complement recent analyses on the engagement of non-governmental organizations (NGOs) in the provision of HIV ⁄ AIDS care in Thailand (Lyttleton et al. 2007; Tantivess & Walt 2008) . The aim of providing this participant-observer's perspective over the last 10 years is to contribute a rich historical analysis of the process of policy change in Thailand. Such perspectives have recently been noted as lacking in the health policy literature, particular in relation to community participation in health policy formulation (Gilson & Raphaely 2008) .
Context: government, civil society and HIV ⁄ AIDS in Thailand
Thailand's HIV epidemic began in 1984, with cases initially confined to perceived 'high-risk' groups: gay men, then injecting drug users and then commercial sex workers. 
Governmental actors
The Government Pharmaceutical Organization is a state enterprise formed in 1966 to provide affordable quality medicines for the public health system. Officials from its Research and Development Institute have, together with other health professionals, taken a public stance on issues of access to medicines at some risk to their professional positions. The Office of Health Care Reform: In 1996, the Ministry of Public Health started a 3-year initiative to increase equity in access to health care, with patient and community involvement. The initiative identified as major concerns lack of access and affordability of drugs for HIV, both for opportunistic infections and antiretroviral therapy (Nitayarumphong 1996) . MSF, TNP+ and ACCESS (see below) co-operated in establishing a standard of prevention and treatment of opportunistic infections at district level. The National Health Security Office: The national health security scheme, promulgated in 2002, partially replaces three previous public insurance schemes and also covers those who were previously uninsured. AIDS NGOs sit on the governing board, as required under the 1997 constitution (Towse et al. 2004 Bank 2000) . In 1991, when more HIV cases were found in the general population, the government vigorously promoted a prevention campaign aiming at 100% condom use in commercial sex establishments (Rojanapithayakorn & Hanenberg 1996) . The campaign is estimated to have prevented 2 million subsequent infections (UNAIDS 2000) . Nevertheless more than one million people have become infected since the epidemic began and more than 400 000 have died.
The first PHA group was established in 1990 in Bangkok. With time, more groups were established and in 1995 their contribution was officially recognized by Ministry of Public Health policy that encouraged the formation of PHA groups within the hospital system. By 2006, there were 900 PHA groups with more than 20 000 members (Lyttleton et al. 2007 ) mainly supported by government funds channelled through public hospitals.
Initially, the engagement of PHA groups in HIV care was focused on social support; advocacy was constrained as groups were isolated from each other and depended on funding from their hospital. This changed with the establishment of the TNP+ in 1998. That year, the Office of Health Care Reform (Table 1) identified lack of accessible HIV treatment as a priority (Nitayarumphong 1996) , and a pilot project to define a standard of treatment for opportunistic infections at district level was established by the Ministry of Public Health, MSF and TNP+ (Revenga et al. 2006) .
Campaigning for access to antiretroviral treatment
Publicly funded (mono-and dual-) antiretroviral therapy was first made available for limited numbers of patients in 1992 (Revenga et al. 2006) . The Ministry of Public Health began to provide triple antiretroviral therapy in 2000 but reliance on expensive brand drugs limited beneficiaries to around 1500 people (Phanuphak 2004) . Large-scale treatment only became possible later, after the Thai Government Pharmaceutical Organisation (GPO) began to produce a range of generic antiretrovirals.
The Government Pharmaceutical Organisation had begun research and development of antiretrovirals in 1992, initially for zidovudine and didanosine. Zidovudine was launched in 1995, but production of generic didanosine was blocked when a Thai patent was granted to BristolMyers Squibb in 1998. The patented version was prohibitively expensive and provoked the first in a series of public demonstrations against intellectual property restrictions to medicines (Limpananont 2002; Wilson et al.1999; Supakakunti et al. 1999) .
At the end of 1999, the GPO submitted a request for a compulsory license, a request backed by public demonstrations in which over 300 PHA gathered outside the Public Health Ministry (Ford et al. 2004) . This was the first occasion in Thailand that HIV positive people braved stigmatization to stage public demonstrations and proved to be a watershed event in terms of their awareness and self-confidence. However, under pressure from the US government (Hecklinger 1999) , the Ministry of Public Health rejected the request. Activists with support from the Law Society (Table 1 ) then mounted a legal challenge against the patent for didanosine, claiming that the patent had been unlawfully granted (Ford et al. 2004) . After 2 years, the court ruled in favour of the plaintiffs, opening the way for generic production.
Campaigning for universal health care
Prior to 2001, Thailand's public health system was accessed through three health insurance systems, but this led to significant exclusion: around three-quarters of the population lacked insurance (United Nations Development Programme 2007) and two-thirds of those with health insurance (those holding low-income health cards) could not access the benefits to which they were entitled (Pramualratana & Wibulpolprasert 2002) . In 2000, civic groups drew up a petition demanding that parliament debate the introduction of universal health insurance (International Labour Organisation 2008) . Under the Royal Thai Government (1997) Constitution, parliament is obliged to debate any petition signed by more that 50 000 voters. TNP+ and the Rural Doctors' Society (Table 1) with their nationwide networks collected the majority of more than 60 000 signatures supporting the petition, forcing a parliamentary debate.
The National Assembly voted against the bill. However, universal health insurance became a key issue in the subsequent election campaign and, fulfilling its election promise, the Thai Rak Thai party introduced health insurance soon after winning the 2001 election, making Thailand one of the first developing countries to provide universal healthcare coverage to their population. Antiretroviral treatment and renal dialysis were initially excluded from the benefits because of their high cost; activists were quick to point out that the constitution prohibits discrimination on account of a particular disease. In October 2001, the Thai GPO manufactured a fixed-dose medicine combination, reducing the price of this regimen from $US 9600 to $US 570 ⁄ patient ⁄ year.
NGO networks promptly demanded government action (Tantivess & Walt 2008) , and the Minister of Public Health announced that antiretroviral drugs would be included in this universal access to healthcare policy, (Phanuphak 2004) . However, it took 4 more years of campaigning before this became a reality (KiatyingAngsulee et al. 2006) .
Increasing the availability of treatment
While efforts were being made to lower the cost of treatment, parallel efforts aimed at increasing its availability. The involvement of PHA in the provision of health care beyond pilot projects began in May 2000, with a Buyers' Club established by TNP+, MSF and ACCESS. While the public health system was relying mostly on brand name drugs, TNP+ purchased generic antiretrovirals from GPO and channelled these drugs to public hospitals via PHA groups; these drugs were prescribed by government doctors, paid for by patients and dispensed by PHA with supervision from the hospital pharmacists (Kreudhutha et al. 2005; Uppakaew 2008 ). This programmes established the principle of partnership at a grassroots level between NGOs and public healthcare providers, and also gave GPO its first orders for several generic antiretrovirals, thus kick starting production. The Buyers' Club was able to scale down its activities as the government programme scaled up.
Concurrently, there was a push to increase access to basic, low-cost medicines for opportunistic infections, which were poorly available prior to their inclusion in the national health insurance scheme in 2001. Surveys carried out by MSF and TNP+ in 2000 found that less than half of symptomatic PHA received co-trimoxazole prophylaxis; access to treatment for other opportunistic infections such as tuberculosis was also limited.
In November 2000, TNP+, MSF and ACCESS launched a project to increase access to prophylaxis and treatment for opportunistic infections, referred to as the 'AIDS can be treated' campaign. It was considered essential that PHA should participate actively in their own treatment and care if they were to develop the knowledge and understanding necessary to stop believing that AIDS was a death sentence. Therefore, the project began by training PHA from 150 groups across the country to recognize symptomatic disease and to support each other in accessing health care. An internal evaluation 2 years after the project began found that access to correct therapeutic interventions for the commonest life-threatening opportunistic infections had increased from less than 50% before the project began to more than 80% (Kumphitak et al. 2004 ).
These experiences showed that with appropriate training and support PHA could develop a role as partners in provision of health care. MSF, ACCESS and TNP+ capitalized on the experiences by developing accessible health education materials and training modules; these were subsequently used to support the government's treatment programme. The chronology of access to HIV treatment is summarised in Table 2 Most PHA group members in Thailand are farm labourers, factory workers or unemployed with only primary education. PHA members working in CCC Centres, in addition to appropriate training to develop their knowledge and skills in provision of care, also need ongoing practical support with such matters as record keeping, teamwork and coordination with the hospital. The training and support is provided by TNP+, MSF and ACCESS.
In addition to providing care and support, the CCC Centres are an attempt to ensure a central involvement of grassroots PHA in the government rollout of antiretroviral therapy. The group must have sought permission from the hospital director, been assigned a room in the hospital to do their work, and hospital staff must have agreed that the PHA can join their HIV care and treatment team. One activist can normally manage a caseload of 15 to 20 clients. Activists are expected to recognize common side effects of antiretroviral drug regimens available in their hospital, about prevention and treatment of three common opportunistic infections (TB, Pneumocystis carinii pneumonia and cryptococcal meningitis) and to be able to provide 'first aid' for symptoms such as fever and diarrhoea, and evaluate treatment adherence. A support team, staffed by members of TNP+, ACCESS and MSF provides training, This support model is a good investment in terms of treatment success and life expectancy (Over et al. 2007 ).
As of mid-2008, antiretroviral treatment was available at all government hospitals, with 180 000 PHA under treatment. One-third (327) of hospitals had established CCC centres, each with 3-10 PHA activists. A Ministry of Public Health ⁄ World Bank study estimated that systematically providing PHA peer support in treatment sites throughout Thailand would increase the cost per life year saved by less Universal health insurance scheme introduced. ART and treatment for renal failure are initially excluded. Civil Society lobbies for inclusion of all treatments. NGOs and PHA appointed to various National Health Security Office subcommittees. In October, the GPO manufactures a fixed-dose combination of ARV (GPO-vir). Following NGO lobbying for government action, minister of Public Health announces that GPO production capacity would be increased and that antiretroviral drugs would be included in the universal access to healthcare policy. CCC Centre model, with PHA as co-providers of care, piloted in two public district hospitals, under MSF supervision. 
Further efforts to increase access to medicines
Civic groups continued pressing for wider access to medicines. An important victory was gained in 2006 when 500 people protested outside the offices of GlaxoSmithKine in Bangkok, forcing withdrawal of a patent application for the drug combination of lamivudine + zidovudine .
Eight years after the GPO requested a compulsory licence for didanosine, the Thai government finally issued compulsory licenses in 2007 and 2008, including for the second-line antiretroviral lopinavir-ritonavir. This followed a WHO evaluation forecasting that the cost of antiretroviral therapy with second-line regimens could cost the country US$ 500 million ⁄ year by 2020 unless action was taken against drug prices (Ministry of Public Health, Thailand & World Health Organisation 2005) .
In addition to these actions against specific patents, civil society groups have worked to promote public health within trade negotiations by mobilizing against US trade pressure for further restrictions via the US-Thai free tradeagreement (FTA) . In 2006, nearly 10 000 protesters gathered outside the venue of the freetrade talks demanding, in line with UN recommendations, that Thailand should not accept any further reinforcement of intellectual property protection proposed in the FTA (Ministry of Public Health et al. 2005) . In response, the Thai Government declared that demands by the United States for Thailand to tighten up drug patenting were 'unacceptable' (Hongthong & Thalang 2006) .
Expanding support to other countries ⁄ diseases
In 2003, ACCESS, MSF and TNP+ set up a project to train participants from Vietnam, Cambodia and Laos, later expanding to Nepal, Myanmar and Yunnan (southern China). While these countries have wide differences in their level of access to HIV ⁄ AIDS care and nature of their civil
PHA clients
Nearly all attend the hospital as patients and most take antiretroviral treatment.
Patients are not obliged to become clients of the CCC Centre, but most of them do so. Relatives may also be CCC Centre clients.
PHA group members
Membership is free and informal. Relatives or friends of PHA are welcome to become members. Numbers fluctuate as new members join or existing members stop attending.
PHA activists 3-10 in each CCC, acting as co-providers of care. society, it has been possible to modify and apply some lessons learned in Thailand in all of these other countries, notably the need to develop a broad network of health workers and NGO staff to ensure ongoing support for PHA.
In 2007, ACCESS and TNP+ expanded the scope of their work by helping patients with chronic renal failure to lobby for access to treatment, and the next year the National Health Security Office began discussing plans to include renal dialysis in the health insurance scheme. This reflects a broader understanding among both government and NGO that access to expensive medicines is not a problem limited to HIV ⁄ AIDS drugs: the Thai government has also investigated the possibility to source generic versions of medicines for cancer, cardiovascular and neuropathic drugs and antibiotics (Cawthorne et al. 2007) .
Conclusions
This paper provides a participant-observers' perspective of the role of civil society activism for access to HIV treatment in Thailand. Such 'insider' perspectives carry the risk of certain biases, in particular in relation to the issues the researcher focuses on and the framing of lessons-learnt towards policy-relevant conclusions rather than generalizable, theoretical themes. We acknowledge that such biases exist in this account, and do not claim this to be a historical perspective of all actors involved in the policy-setting process. Nevertheless, participant observation holds a critical place in health policy analysis as it allows for a degree of access to information, understanding of culture and authenticity that is not readily available to an external researcher .
As our account illustrates, PHA have made an essential contribution to overall provision of treatment and care in Thailand, to the point that some have concluded that the scale up and sustainability of antiretroviral therapy (ART) in Thailand would not have been possible without the engagement of civil society networks (Tantivess & Walt 2008) . The role of these groups has been one of both co-operation (providing concrete support for patients and for the health system as a whole) and challenge (advocating for increased access to treatment as a human right). Their efforts contributed substantially to the availability of affordable generic medicines, early treatment for opportunistic infections and an informed and responsible approach towards antiretroviral treatment that is supportive of good adherence and treatment success.
Since 1990, the role of PHA in providing peer support has been increasingly accepted and encouraged in Thailand. A change in perception of PHA from 'passive receiver' to 'co-provider' of health care came about due to their own action, with significant support from local and international NGOs. Improved acceptance of and support for PHA by the healthcare system followed. A few years ago, health care for PHA was mainly provided by specialist centres; today, nearly every hospital in Thailand accepts its responsibility to provide care for PHA and the gap between doctors and patients has been markedly reduced, with over one third of all hospitals including a formal role for PHA through the CCC model. Increased control over their own health has also brought benefits for PHA in terms of selfimage, confidence, and dignity. Empowerment has come from the recognition that many of the barriers to carelack of access to affordable medicines, lack of national drug supply and lack of peer support -are barriers they have been able to overcome themselves. These successes have firmly established the role of patients not just as beneficiaries of the health system, but stakeholders in its development.
With Thailand virtually reaching the goal of universal access to antiretroviral treatment, the access to medicines crisis that TNP+ confronted in 1998 is largely resolved. But access for unregistered groups, principally ethnic minorities and migrant populations, who account for more than 2 million people in Thailand, remains very limited. Specific vulnerabilities make these groups at high risk from contracting HIV ⁄ AIDS. Other high-risk groups such as sex workers and injecting drug users continue to have difficulty accessing the health system (Ainsworth et al. 2003) . TNP+ and ACCESS are advocating to extend the reach of the public ART system to these marginalized groups, and have negotiated with the Thai government to ensure that a proportion of the Global Fund grant goes towards supporting these groups.
Successful campaigning for access to affordable medicines has depended on strong working relationships between PHA, academics, NGOs, key government officials and journalists who have been willing to take the time to understand complex issues. This activism has been supportive of, rather than antagonistic towards, government: pushing the government to increase availability of affordable antiretrovirals, and then providing practical support to the implementation of treatment programmes when the medicines become available.
However, with first-line treatment available nationwide and with PHA taking a formal role in policy formulation, there is no longer a single urgent common cause for which to fight. Challenges now faced by Thai civic groups, and which need to be prioritized, include lack of a once-daily first-line regimen, of fixed-dose combinations of ART for children and of TB medication, of wider access to second-line treatment, treatment for Hepatitis C and harm reduction programmes for infecting drug users. Perhaps, most pressing however, is how to maintain the quality of CCC Centre services if funding for their support system is withdrawn.
